This article is part of the supplement: 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Poster presentation
Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
-
* Corresponding author: Christian Scheerans christian.scheerans@bayer.com
Bayer HealthCare AG, Wuppertal, Germany
BMC Pharmacology 2011, 11(Suppl 1):P61 doi:10.1186/1471-2210-11-S1-P61
Published: 1 August 2011First paragraph (this article has no abstract)
Cinaciquat (CIN) is a guanylate cyclase (sGC) activator that induces cyclic GMP generation and vasodilation preferentially in diseased vessels [1]. CIN has the potential to increase cardiac output in patients with acute decompensated heart failure [2]. CIN is predominantly and rapidly cleared by the liver [3], and thus, it was not expected that the kidney function would have an influence on CIN clearance. Nevertheless, we determined the pharmacokinetics of CIN in individuals with renal impairment and age- and gender-matched healthy volunteers with normal renal function [4].